CIAM
ADIL

Caitong International Asset Management’s Adial Pharmaceuticals ADIL Stock Holding History

Caitong International Asset Management’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27 Buy
+15
New +$53 ﹤0.01% 2055

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Caitong International Asset Management's ADIL Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Adial Pharmaceuticals (ADIL) in Q1 2026: 15 shares worth $27. The stake represents ﹤0.01% of the portfolio and ranks #2055 among its holdings.

14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • Caitong International Asset Management held 15 shares of Adial Pharmaceuticals worth $27 as of Q1 2026.
  • Adial Pharmaceuticals was a new Caitong International Asset Management position in Q1 2026.
  • Adial Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2055 holding.
  • 14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.